Navigation Links
Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
Date:12/28/2007

NEW YORK, Dec. 28 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) will hold an investor conference call on Thursday, January 3, 2008, at 1 PM (ET) to present an update on the Company's safety study for pafuramidine, the Company's oral drug candidate. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. The User Access Code is #29746958. To register, please call no later than 10 minutes prior to the scheduled start of the call. Information to access a recording of the conference call will be available starting on January 10, 2008 from the Immtech Pharmaceuticals website (http://www.immtechpharma.com).

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the Company is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT or African sleeping sickness), malaria and a well defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please visit the Company's website at http://www.immtechpharma.com

This press release contains forward-looking statements regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are forward-looking statements and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) Immtech's potential exposure to significant product liability.

Additional risks are discussed in Immtech's current filings with the Securities and Exchange Commission. Although Immtech believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward- looking statement, whether as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Completes Malaria Prevention Trial
2. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
5. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
6. Exponent to Present at the Upcoming Sidoti & Company Investor Forum and William Blair Small-Cap Growth Stock Conference
7. Stryker to Present at Investor Conference
8. AMERIGROUP Corporation to Host Investor Day
9. Milestone Scientific to Present at the Edgewater Research Investor Conference
10. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
11. Par Pharmaceutical Provides Summary of Analyst/Investor Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Many RNA binding ... principles, the research team developed expressRNA, a web platform encompassing computational tools for ... at nucleotide resolution the ‘RNA maps’, which demonstrate that RBPs bind to specific ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage (UA), ... seven new products designed to create tailored looks and athleisure-inspired outfits. UA Flex fabric ... easy care stretch twill. , With trendy looks hitting the medical community, UA Flex ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... agency, recently became re-accredited by the Joint Commission, which accredits and certifies ... and certification is recognized nationwide as a symbol of quality that reflects an ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River ... aboard the line’s latest all-inclusive boutique ship, S.S. Joie de Vivre . What ... specifically for cruising France’s Seine River and designed small enough to dock directly in ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water advocate Sharon Kleyne ... Hour Power of Water, Global Climate Change and Your Health on VoiceAmerica sponsored ... and how it affects the human eyes. , According to Sharon Kleyne ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... Pa. , June 19, 2017  Researchers from ... today that they will host a live, complimentary webinar ... from the benchtop to the real world" on Wednesday ... EDT. This webinar will feature interviews ... rare look into the manipulation techniques abusers use to ...
(Date:6/14/2017)...  ivWatch LLC, a medical device company focused on ... is pleased to announce it was the Bronze Winner ... and Equipment at the 2017 Medical Design Excellence Awards ... The award was presented by Medical Device and Diagnostics ... New York during MD&M East, ...
(Date:6/13/2017)... WARSAW, Ind. , June 13, 2017 Zimmer ... in musculoskeletal healthcare, today announced that the U.S. Food and ... Letter dated June 3, 2015 relating to its ... "The successful clearance of ... China manufacturing facility is a measure of the ...
Breaking Medicine Technology: